SafeDelivery Specific delivery of active biomolecules to treat lung cancer
- Coordinator
- Fundacio Centre De Regulacio Genomica, Spain
- Runs
- 1 November 2026 to 31 October 2031
- Status
- Running
- EU funding
- €3.3m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101266773
What the project is doing
In the project's own words, from its summary on CORDIS.
Lung cancer is the second most common cancer and one of the most lethal types, with few effective treatment options. Potent biologics often fail clinically due to systemic toxicity, as they cannot be selectively delivered or activated at the tumour site. Immunotherapy exemplifies this: while established in cancer care, its use is often limited by severe side effects. This underscores the need for technologies enabling precise tumour targeting and local immune activation.
SafeDelivery will overcome this limitation by creating a programmable therapeutic platform that minimizes systemic toxicity by activating biologics exclusively at the tumour site. Our innovation lies in uniting two powerful technologies: our protein design FoldXpro software with AI-enhanced modules, to enable quantitative and specific protein masking (not functional util masking is removed), and Mycochassis, a cell-wall-deficient lung bacterial vector.
FoldXpro will define quantitative rules for designing protein masking with predictable activity profiles. Mycochassis will be engineered to produce vesicles carrying RNA and proteins to selectively reprogram cancer cells, and to secrete or display enzymes that locally activate systemically administered masked biologics only within the tumour microenvironment. This represents the first (therapeutic) platform to integrate masking with in situ activation by a lung-tropic live vector.
We will apply this strategy to chemokines, cytokines, and nanobodies active in tumours but limited by systemic toxicity. Designed molecules, will be validated in vitro, ex-vivo and in vivo using a lung cancer mouse model as proof of concept. By integrating programmable protein masking with in situ bacterial delivery and activation, this work opens a new therapeutic paradigm for safe specific delivery of biologics. Beyond lung cancer, it will establish a generalizable framework for designing conditionally active proteins, enabling safer biologics for a range of diseases.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Centre De Regulacio Genomica | Barcelona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI